Results 211 to 220 of about 163,730 (308)
Predicting Durable Anti-tumor Immune Responses after Cancer Vaccines. [PDF]
Liao JB, Disis ML.
europepmc +1 more source
Novel Organelle‐Based Intracellular Immunity With Mechanistic and Therapeutic Implications
A conceptual framework illustrating how PAMPs/DAMPs initiate barrier, innate, adaptive, and intracellular immune responses, with organelle‐based intracellular immunity serving as a central integrator linking metabolism, inflammatory signaling, and therapeutic interventions to restore immune homeostasis.
Keman Xu +9 more
wiley +1 more source
Prospects and Challenges of Lung Cancer Vaccines. [PDF]
Lin Z, Chen Z, Pei L, Chen Y, Ding Z.
europepmc +1 more source
Abstract Background and aims The heart is a metabolic organ rich in mitochondria. The failing heart reprograms to utilize different energy substrates, which increase its oxygen consumption. These adaptive changes contribute to increased oxidative stress.
Qinghong Li +12 more
wiley +1 more source
Breast cancer vaccines: from immune promise to the prospect of eradication. [PDF]
Imtiaz A +3 more
europepmc +1 more source
Vaccination in women with cancer.
Nilma Antas Neves +5 more
openaire +2 more sources
The Possibilities of a Vaccine for Cancer [PDF]
openaire +2 more sources
Enhancing Optogenetics‐Based Cancer Therapy Via Nanotechnology
Nanotechnology enhances optogenetics‐based cancer therapy through improved delivery systems and non‐invasive optical regulation. It further enables precise and programmable control of optogenetic living therapeutics for localized antitumor responses.
Honggang Shen +8 more
wiley +1 more source
Lung cancer vaccines to enhance immune checkpoint inhibitor therapy: evidence and future perspectives. [PDF]
Tang Z, Zha L, Liang R, Li T.
europepmc +1 more source
ABSTRACT Objective To provide a comprehensive review of the biological rationale, clinical evidence, and practical perioperative management of immunotherapy for the head and neck surgeon. Summary Background Data Standard treatment for resectable head and neck squamous cell carcinoma (HNSCC) has reached a survival plateau, with over 50% of patients ...
Nicholas Brian Shannon, Bruce Ashford
wiley +1 more source

